Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Rectal DuoGel (IQP-0528)
NCT03082690Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Nov 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DuoGel in human immunodeficiency virus infection (HIV), sponsored by Johns Hopkins University. Primary endpoints: Systemic and Local Safety at 1 week, Rectal Pharmacokinetics at 72 hours and 4 more. Started Nov 2017; status: completed.
02
Drugs
DuoGel
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03082690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082690.